1. Hem
  2. Products
  3. Elocta
  4. Efficacy
  5. Bleed protection
Se-Elocta-0

Bleed protection1–4

ELOCTA offers comprehensive protection for adults and adolescents1,2

The efficacy of ELOCTA in adults and adolescents has been established across multiple clinical settings.1,2

In ASPIRE, with 4.5 years median cumulative treatment duration, adults and adolescents receiving individualised prophylaxis with ELOCTA achieved:2

Elevate bleed protection

ELOCTA also provided:
• Effective bleed resolution1
• 87% of bleeds were resolved with 1 injection of ELOCTA
• Comprehensive protection during surgery2
• 74% of major surgeries required 1 injection of ELOCTA to maintain haemostasis effectively during the surgical procedure

ELOCTA provides comprehensive protection for children2,3

The efficacy of ELOCTA has been established in previously treated paediatric patients.

In Kids A-LONG and ASPIRE, ELOCTA provided effective bleed protection:2,3

Adapted from Young G, et al. J Thromb Haemost 2015 and Nolan B, et al. Haemophilia 2020.

Adapted from Young G, et al. J Thromb Haemost 2015 and Nolan B, et al. Haemophilia 2020.

In patients <12 years old:
• 81.4% of bleeds were resolved with 1 injection of ELOCTA3

ELOCTA offers proven protection for previously untreated patients4

The efficacy of ELOCTA has been established in previously untreated patients.
In PUPs A-LONG, previously untreated patients who received prophylaxis with ELOCTA achieved:4
• 1.49 median overall ABR
• ZERO median spontaneous ABR
• ZERO median joint ABR

ELOCTA provided effective bleed resolution in previously untreated patients:4
• Most bleeds resolved with 1 injection of ELOCTA

ABR, annualised bleed rate; FVIII, factor VIII; SHL, standard half-life.

References

1. Mahlangu J, et al. Blood 2014;123(3):317–325. 2. Nolan B, et al. Haemophilia 2020;26(3):494–502. 3. Young G, et al. J Thromb Haemost 2015;13(6):967–977. 4. Königs C. et al. Blood. 2022;139(26):3699-3707.

PP-18595
Other sites
expand_less